Printer Friendly

BARR LABORATORIES ANNOUNCE RESTRUCTURING

 BARR LABORATORIES ANNOUNCE RESTRUCTURING
 POMONA, N.Y., April 29 /PRNewswire/ -- Barr Laboratories (AMEX: BRL)


announced a restructuring today as a result of Food and Drug Administration (FDA) actions against Barr over the past 12 months, which have prevented Barr from receiving new drug approvals, improving manufacturing procedures, or selling to federal agencies. The restructuring will result in a temporarily reduced product line and a reduction in workforce of approximately 25 percent.
 The FDA placed Barr on the "Alert List," an extra-legal device used by the FDA. Barr has sued the FDA to enjoin them from enforcing the "Alert List" as well as to enjoin the FDA from enforcing "informal" and often conflicting policy statements of FDA officials that are not subject to the normal and required rulemaking process.
 As an expression of Barr's good faith, in the hopes of a swift settlement of these issues, Barr is temporarily reducing its product line. The products Barr is temporarily suspending are those which are affected by newly articulated informal FDA policies. All of these products are safe and effective for their intended use, and are in strict conformance with all applicable U.S.P. standards. Barr is not withdrawing any ANDAs and expects to return the suspended products to the market.
 Although the company has not yet released results for the quarter ended March 31, it expects to report a loss for that quarter. In the current quarter, the company expects to take a one-time restructuring charge of $500,000.
 Barr has been cooperating with lengthy FDA onsite visits and investigations for the past 13 months, and negotiating with the FDA for the past six months in an attempt to resolve these issues. During its most recent inspection reports in March 1992, the FDA acknowledged that Barr had already met the commitments raised by the June-September 1991 inspection. The FDA's ongoing investigations have uncovered no incidents of fraud, misrepresentation, deception or any similar unlawful acts. Despite Barr's compliance, Barr continues to remain on the FDA's "Alert List."
 -0- 4/29/92
 /CONTACT: Edwin A. Cohen of Barr Laboratories, 914-362-1100/
 (BRL) CO: Barr Laboratories ST: New York IN: MTC SU: RCN


SM-TS -- NY020 -- 4271 04/29/92 10:27 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 29, 1992
Words:367
Previous Article:EUROSTAR MINIVAN PLANT DEDICATED IN AUSTRIA; FIRST MANUFACTURING VENTURE IN EUROPE FOR CHRYSLER IN 15 YEARS
Next Article:ALAN R. BATKIN AND O.J. SIMPSON TO JOIN THE BOARD OF INFINITY BROADCASTING CORPORATION


Related Articles
BARR LABORATORIES ANNOUNCES ADDITIONAL ASSESSMENT
BARR LABORATORIES RESTRUCTURES
FDA Approves Barr's Danazol; First New Product in Barr Laboratories' Hormonal Category
Barr Launches 20 mg Megestrol Acetate Tablet; Rounds-Out Megestrol Solid Oral Dosage Line
Barr Launches Tamoxifen Citrate 20mg Tablets
Barr Laboratories Announces Stock Split Distribution
Barr Laboratories to Market Warner Chilcott's Minocycline Anti-Microbial; First Product Resulting from Marketing/Manufacturing Corporate Collaboration
Barr Laboratories Begins Trading on New York Stock Exchange
Barr Laboratories Completes Common Stock Offering
Barr Receives First Approval for Generic Revia(R) Tablets; Used in Treatment of Alcohol Dependence and to Block Effects of Opioids

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters